Medivation (MDVN) Hits New Lifetime High

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Medivation ( MDVN) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Medivation as such a stock due to the following factors:

  • MDVN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $94.9 million.
  • MDVN has traded 19,359 shares today.
  • MDVN is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDVN with the Ticky from Trade-Ideas. See the FREE profile for MDVN NOW at Trade-Ideas

More details on MDVN:

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. MDVN has a PE ratio of 317.3. Currently there are 10 analysts that rate Medivation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

The average volume for Medivation has been 906,700 shares per day over the past 30 days. Medivation has a market cap of $7.1 billion and is part of the health care sector and drugs industry. The stock has a beta of -0.45 and a short float of 6.7% with 3.86 days to cover. Shares are up 42.6% year-to-date as of the close of trading on Friday.

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors